Dataset opportunity
Icentia — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Icentia, usable for Diagnostic AI and Computer Vision.
Score
66.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Cardiology market was valued at USD 1.7 billion in 2025, projected to reach USD 14.8 billion by 2033, at a CAGR of 31.2% (2026-2033) (source: Grand View Research). [1]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-29
HHS details takeaways from sweeping AI request for information
medtechdive.com ↗ - 📰press2026-06-29
J&J starts pivotal trials of Shockwave IVL device in carotid arteries
medtechdive.com ↗ - 📰press2026-06-26
Aidoc wins breakthrough nod for AI that reads chest X-rays
medtechdive.com ↗ - 📰press2026-06-26
Agilent finalizes Biocare Medical takeover
medtechdive.com ↗ - 📰press2026-06-25
Labcorp rolls out colorectal cancer screening test nationwide
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 🧑💻Hiring a data role
Recruitment for R&D and AI-related roles in medical signal processing
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Icentia possesses a substantial Medical Imaging dataset comprised of continuous electrocardiogram (ECG) waveforms. This data is uniquely generated via its proprietary CardioSTAT ambulatory IoT monitoring hardware, ensuring a high-volume, consistent, and rare source of information linked to patient medical records. The dataset's structure and proprietary origin make it exceptionally valuable for developing and validating high-performance Diagnostic AI algorithms for cardiac arrhythmia detection.
The global AI in Cardiology market was valued at USD 1.7 billion in 2025 and is projected to grow at a remarkable CAGR of 31.2%. [1] This explosive growth underscores the intense demand for specialized cardiac data. Despite significant access complexities, including strict HIPAA/GDPR compliance and the need to verify patient consent for secondary use, the rarity and high-fidelity nature of this dataset represent a critical asset for AI developers aiming to capture a share of this $14.8 billion projected market. [1] ⚠ Diligence (valuable data, access to negotiate): Highly sensitive medical data requiring strict HIPAA/GDPR compliance; Data is generated via proprietary medical hardware (CardioSTAT); Patient consent for secondary use of data must be verified; Company already provides AI-driven analysis, suggesting high internal data value awareness · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Icentia owns a massive, proprietary dataset of over 2 billion expert-annotated heartbeats from 11,000 patients. This clinical-grade data is a foundational asset for companies building next-generation diagnostic AI to detect cardiac arrhythmias. In a global AI in Cardiology market projected to exceed USD 14 billion by 2033, this rare, high-volume dataset offers a significant competitive advantage for developing and validating highly accurate algorithms.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume68
3 evidence hits, explicit data-volume mention
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand92
Buyer demand is exceptionally high, driven by the rapidly expanding AI in Cardiology market which has a projected CAGR of 31.2%, creating urgent demand for proprietary, high-quality ECG data to train diagnostic models. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Icentia is a good target as it's an SME whose core business is a medical device (CardioSTAT) and an associated patient-specific diagnostic service, not selling data or AI software; the vast ECG dataset generated is a valuable, dormant by-product. Issues: The company offers an 'ECG data analysis service' and 'proprietary software' for analysis. [9, 10] This suggests they are already monetizing intelligence derive; Icentia has previously donated a large, anonymized dataset to the p
- Deep Qualification90
⚠ needs review — Icentia provides medical devices and associated analysis services, it does not sell data as a core product. The data is highly restricted, and the 'Medical Imaging' label is inaccurate as they deal with ECG signals. [licensing restricted; dataset_type implausible vs real activity: The opportunity is labeled 'Medical Imaging Dataset', but the company's product, CardioSTAT, records electrocardiogram (ECG) waveforms, which are electrical signals, not medical images. [10, 14]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The dataset contains records from 11,000 patients, including 2 billion annotated beats captured via the proprietary CardioSTAT device, providing the scale and diversity required to train robust AI models.
IoT / sensor data
This consists of high-quality, continuous ECG recordings for up to 14 days per patient, offering the long-duration temporal data essential for developing algorithms that can identify intermittent and subtle cardiac events.
Data-volume signal
The holder possesses a vast volume of billions of beats accompanied by expert-level annotations, creating a definitive ground-truth resource for training and validating AI models targeting a wide range of cardiac arrhythmias.
Coverage
Scanned sources
Deliverable
Premium dataset report
Icentia Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Cardiology market was valued at USD 1.7 billion in 2025, projected to reach USD 14.8 billion by 2033, at a CAGR of 31.2% (2026-2033) (source: Grand View Research). [1]. Investment score 66.9/100 (confidence 0.49). Recommended action: Data Sharing Agreement.